A股異動 | 七彩化學(300758.SZ)漲逾6% 定增方案獲批
格隆匯11月13日丨昨日大跌9.8%的七彩化學(300758.SZ)股價迎來反彈,現報25元,漲幅6.6%,最新總市值48億。公司昨日公告稱,向特定對象發行股票申請獲中證監註冊批覆。此外,擬參與投資紹興上虞易豐一期股權投資合夥企業(有限合夥),基金主要投資於新材料產業鏈中的成長型、創新型和平台型企業或項目以及新材料產業中具備良好市場前景、擁有核心技術的高成長科技型企業,規模2億元人民幣,公司出資1000萬元認繳基金份額,佔基金認繳出資總額比例的5.8140%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.